MANE (MANE) Competitors

$101.42 -0.20 (-0.19%)

Closing price 05/22/2026 03:59 PM Eastern

Extended Trading

$103.00 +1.58 (+1.55%)

As of 05/22/2026 07:39 PM Eastern

MANE vs. RGC, SMMT, BBIO, AXSM, and RDY

Should you buy MANE stock or one of its competitors? MarketBeat compares MANE with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MANE include Regencell Bioscience (RGC), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.

How does MANE compare to Regencell Bioscience?

MANE (NYSE:MANE) and Regencell Bioscience (NASDAQ:RGC) are both manufacturing companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

In the previous week, Regencell Bioscience had 10 more articles in the media than MANE. MarketBeat recorded 13 mentions for Regencell Bioscience and 3 mentions for MANE. MANE's average media sentiment score of 0.46 beat Regencell Bioscience's score of 0.00 indicating that MANE is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MANE	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

MANE currently has a consensus target price of $100.00, suggesting a potential downside of 1.40%. Given MANE's stronger consensus rating and higher probable upside, equities analysts clearly believe MANE is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MANE	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
MANE	N/A	N/A	N/A
Regencell Bioscience	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MANE	N/A	N/A	N/A	N/A	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

0.1% of Regencell Bioscience shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

MANE beats Regencell Bioscience on 4 of the 7 factors compared between the two stocks.

How does MANE compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and MANE (NYSE:MANE) are both pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, Summit Therapeutics had 3 more articles in the media than MANE. MarketBeat recorded 6 mentions for Summit Therapeutics and 3 mentions for MANE. Summit Therapeutics' average media sentiment score of 0.55 beat MANE's score of 0.46 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MANE	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

4.6% of Summit Therapeutics shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
MANE	N/A	N/A	N/A	N/A	N/A

Summit Therapeutics currently has a consensus price target of $26.05, suggesting a potential upside of 56.76%. MANE has a consensus price target of $100.00, suggesting a potential downside of 1.40%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than MANE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.35
MANE	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

MANE's return on equity of 0.00% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
MANE	N/A	N/A	N/A

Summary

Summit Therapeutics beats MANE on 7 of the 10 factors compared between the two stocks.

How does MANE compare to BridgeBio Pharma?

MANE (NYSE:MANE) and BridgeBio Pharma (NASDAQ:BBIO) are both pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

99.9% of BridgeBio Pharma shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MANE has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%.

Company	Net Margins	Return on Equity	Return on Assets
MANE	N/A	N/A	N/A
BridgeBio Pharma	-124.42%	N/A	-65.81%

MANE currently has a consensus target price of $100.00, indicating a potential downside of 1.40%. BridgeBio Pharma has a consensus target price of $88.90, indicating a potential upside of 28.62%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than MANE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MANE	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
BridgeBio Pharma	1 Sell rating(s)	1 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.88

In the previous week, BridgeBio Pharma had 12 more articles in the media than MANE. MarketBeat recorded 15 mentions for BridgeBio Pharma and 3 mentions for MANE. BridgeBio Pharma's average media sentiment score of 0.47 beat MANE's score of 0.46 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MANE	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MANE has higher earnings, but lower revenue than BridgeBio Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MANE	N/A	N/A	N/A	N/A	N/A
BridgeBio Pharma	$502.08M	26.96	-$724.93M	-$3.74	N/A

Summary

BridgeBio Pharma beats MANE on 8 of the 10 factors compared between the two stocks.

How does MANE compare to Axsome Therapeutics?

MANE (NYSE:MANE) and Axsome Therapeutics (NASDAQ:AXSM) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

In the previous week, MANE had 1 more articles in the media than Axsome Therapeutics. MarketBeat recorded 3 mentions for MANE and 2 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.65 beat MANE's score of 0.46 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MANE	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Axsome Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MANE has higher earnings, but lower revenue than Axsome Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MANE	N/A	N/A	N/A	N/A	N/A
Axsome Therapeutics	$638.50M	19.02	-$183.17M	-$3.73	N/A

MANE presently has a consensus price target of $100.00, suggesting a potential downside of 1.40%. Axsome Therapeutics has a consensus price target of $251.26, suggesting a potential upside of 6.48%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than MANE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MANE	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

MANE has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. MANE's return on equity of 0.00% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MANE	N/A	N/A	N/A
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

81.5% of Axsome Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Axsome Therapeutics beats MANE on 8 of the 12 factors compared between the two stocks.

How does MANE compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and MANE (NYSE:MANE) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to MANE's net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.16% beat MANE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.16%	8.12%
MANE	N/A	N/A	N/A

In the previous week, MANE had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 3 mentions for MANE and 0 mentions for Dr. Reddy's Laboratories. MANE's average media sentiment score of 0.46 beat Dr. Reddy's Laboratories' score of 0.00 indicating that MANE is being referred to more favorably in the news media.

Company	Overall Sentiment
Dr. Reddy's Laboratories	Neutral
MANE	Neutral

Dr. Reddy's Laboratories has higher revenue and earnings than MANE.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.17	$484.20M	$0.58	23.44
MANE	N/A	N/A	N/A	N/A	N/A

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Dr. Reddy's Laboratories currently has a consensus price target of $16.90, suggesting a potential upside of 24.30%. MANE has a consensus price target of $100.00, suggesting a potential downside of 1.40%. Given Dr. Reddy's Laboratories' higher possible upside, research analysts plainly believe Dr. Reddy's Laboratories is more favorable than MANE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MANE	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Dr. Reddy's Laboratories beats MANE on 7 of the 11 factors compared between the two stocks.

Get MANE News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MANE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MANE vs. The Competition

Export

Metric	MANE	Pharmaceutical Preparations Industry	Manufacturing Sector	NYSE Exchange
Market Cap	$4.24B	$927.43M	$4.26B	$23.20B
Dividend Yield	N/A	4.84%	5.93%	4.10%
P/E Ratio	N/A	1.46	21.90	30.65
Price / Sales	N/A	119.63	180.55	24.50
Price / Cash	N/A	20.07	55.68	25.12
Price / Book	N/A	7.59	34.85	4.74
Net Income	N/A	-$3.64M	$112.32M	$1.07B
7 Day Performance	0.54%	1.93%	2.55%	1.45%
1 Month Performance	49.90%	76.78%	3.54%	1.58%
1 Year Performance	N/A	126.62%	15.79%	28.44%

MANE Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MANE MANE	N/A	$101.42 -0.2%	$100.00 -1.4%	N/A	$4.24B	N/A	N/A	19
RGC Regencell Bioscience	0.4801 of 5 stars	$28.58 flat	N/A	N/A	$14.13B	N/A	N/A	10
SMMT Summit Therapeutics	3.0156 of 5 stars	$16.87 flat	$27.58 +63.5%	-35.7%	$13.09B	N/A	N/A	110	Analyst Downgrade
BBIO BridgeBio Pharma	3.5122 of 5 stars	$66.13 flat	$88.19 +33.4%	+107.3%	$12.95B	$502.08M	N/A	400	Gap Up
AXSM Axsome Therapeutics	2.6129 of 5 stars	$227.72 flat	$251.26 +10.3%	+124.6%	$11.72B	$638.50M	N/A	380

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:MANE) was last updated on 5/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MANE (MANE) Competitors

MANE vs. RGC, SMMT, BBIO, AXSM, and RDY

How does MANE compare to Regencell Bioscience?

Summary

How does MANE compare to Summit Therapeutics?

Summary

How does MANE compare to BridgeBio Pharma?

Summary

How does MANE compare to Axsome Therapeutics?

Summary

How does MANE compare to Dr. Reddy's Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MANE vs. The Competition

MANE Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MANE (MANE) Competitors

MANE vs. RGC, SMMT, BBIO, AXSM, and RDY

How does MANE compare to Regencell Bioscience?

Does the media refer more to MANE or RGC?

Do analysts prefer MANE or RGC?

Is MANE or RGC more profitable?

Which has higher valuation and earnings, MANE or RGC?

Do insiders and institutionals hold more shares of MANE or RGC?

Summary

How does MANE compare to Summit Therapeutics?

Does the media favor SMMT or MANE?

Do insiders & institutionals hold more shares of SMMT or MANE?

Which has better valuation and earnings, SMMT or MANE?

Do analysts rate SMMT or MANE?

Is SMMT or MANE more profitable?

Summary

How does MANE compare to BridgeBio Pharma?

Do insiders & institutionals have more ownership in MANE or BBIO?

Is MANE or BBIO more profitable?

Do analysts recommend MANE or BBIO?

Does the media refer more to MANE or BBIO?

Which has better earnings and valuation, MANE or BBIO?

Summary

How does MANE compare to Axsome Therapeutics?

Does the media prefer MANE or AXSM?

Which has preferable earnings and valuation, MANE or AXSM?

Do analysts prefer MANE or AXSM?

Is MANE or AXSM more profitable?

Do insiders and institutionals hold more shares of MANE or AXSM?

Summary

How does MANE compare to Dr. Reddy's Laboratories?

Is RDY or MANE more profitable?

Does the media favor RDY or MANE?

Which has higher earnings and valuation, RDY or MANE?

Do insiders & institutionals hold more shares of RDY or MANE?

Do analysts prefer RDY or MANE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MANE vs. The Competition

MANE Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools